Literature DB >> 21320644

The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis.

Yu-Tsan Lin1, Chen-Ti Wang, M Eric Gershwin, Bor-Luen Chiang.   

Abstract

Juvenile idiopathic arthritis (JIA) has had a long and difficult problem with classification. It is clearly a heterogeneous and multi-factorial autoimmune disease but all too often the distinctions among subtypes were unclear. In fact, there is now increasing evidence of a distinct pathogenesis of oligo/polyarticular JIA compared to systemic JIA. Oligo/polyarticular JIA is an antigen-driven lymphocyte-mediated autoimmune disease with abnormality in the adaptive immune system. Cartilage-derived auto-antigens activate autoreactive T cells including Th1 and Th17 cells with production of pro-inflammatory cytokines IFN-γ and IL-17. On the other hand, the inhibition of regulatory T (Treg) cells including natural Foxp3(+) Treg and self-heat shock protein-induced Treg cells with decreased anti-inflammatory cytokine IL-10 results in the loss of immune tolerance. Imbalance between autoreactive Th1/Th17 and Treg cells leads to the failure of T cell tolerance to self-antigens, which contributes to the synovial inflammation of oligo/polyarticular JIA. By contrast, systemic JIA is an autoinflammatory disease with abnormality in the innate immune system. A loss of control of the alternative secretory pathway leading to aberrant activation of phagocytes including monocytes, macrophages and neutrophils seems to be involved in the release of pro-inflammatory cytokines IL-1, IL-6, IL-18 and pro-inflammatory S100-proteins, which contribute to the multisystem inflammation of systemic JIA. Markedly distinct pathogenesis of oligo/polyarticular JIA and systemic JIA implies that they might need different treatment strategies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320644     DOI: 10.1016/j.autrev.2011.02.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  49 in total

Review 1.  What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?

Authors:  Rolando Cimaz; Davide Moretti; Ilaria Pagnini; Achille Marino; Luca Cantarini; Gabriele Simonini
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  Antinuclear Antibody-Positive Juvenile Idiopathic Arthritis Despite IRAK-4 Deficiency.

Authors:  Boris Hügle; Norman Händel; Klaus Schwarz; Michael Borte; Volker Schuster
Journal:  J Clin Immunol       Date:  2018-04-29       Impact factor: 8.317

3.  Atopy in children with the enthesitis-related arthritis (ERA) subtype of juvenile idiopathic arthritis is associated with a worse outcome.

Authors:  Ruru Guo; Lanfang Cao; Xianming Kong; Haiyan Xue; Xiaoli Li; Lijuan Shen
Journal:  Eur J Pediatr       Date:  2015-05-03       Impact factor: 3.183

4.  Serum microRNAs as Potential Biomarkers of Juvenile Idiopathic Arthritis.

Authors:  Yasuko Kamiya; Jun-ichi Kawada; Yoshihiko Kawano; Yuka Torii; Shinji Kawabe; Naomi Iwata; Yoshinori Ito
Journal:  Clin Rheumatol       Date:  2015-04-07       Impact factor: 2.980

5.  Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.

Authors:  Ennio Giulio Favalli; Irene Pontikaki; Andrea Becciolini; Martina Biggioggero; Nicola Ughi; Micol Romano; Chiara Crotti; Maurizio Gattinara; Valeria Gerloni; Antonio Marchesoni; Pier Luigi Meroni
Journal:  Clin Rheumatol       Date:  2017-06-08       Impact factor: 2.980

6.  MEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritis.

Authors:  Hala M Lotfy; Manal E Kandil; Marianne Samir Makboul Issac; Samia Salah; Nagwa Abdallah Ismail; Mohamed A Abdel Mawla
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 7.  Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Fabio Martinon; Alexandre Belot; Thomas Henry; Pascal Sève
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

8.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

9.  Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Authors:  Cristina C Clement; Halima Moncrieffe; Aditi Lele; Ginger Janow; Aniuska Becerra; Francesco Bauli; Fawzy A Saad; Giorgio Perino; Cristina Montagna; Neil Cobelli; John Hardin; Lawrence J Stern; Norman Ilowite; Steven A Porcelli; Laura Santambrogio
Journal:  JCI Insight       Date:  2016-02-25

10.  Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity.

Authors:  Tamer A Gheita; Iman I El-Gazzar; Reem I El Shazly; Abeer M Nour El-Din; Enas Abdel-Rasheed; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-08-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.